Therefore, pharmacologically inhibiting the cGAS/STING pathway and consecutively inflammation might be beneficial in treating DKD, especially in certain groups, such as aged males, where this pathway is highly elevated. This evidence concerns the gene STING1 and diabetic kidney disease.